Catalent Pharmaceutical Technology (Shanghai)

Catalent Pharmaceutical Technology (Shanghai) is a specialized facility of Catalent, a premier global contract development and manufacturing organization (CDMO). Located in the Waigaoqiao Free Trade Zone, the site serves as a strategic hub for clinical supply services in China and the broader Asia-Pacific region. Its capabilities include primary and secondary packaging, clinical storage, and global distribution, specifically tailored to support international and domestic clinical trials. The facility also provides access to Catalent's proprietary drug delivery technologies, such as Zydis fast-dissolve tablets and softgel formulation expertise. By integrating local expertise with global quality standards, the Shanghai site enables biopharmaceutical companies to navigate the Chinese regulatory landscape and accelerate speed-to-market. Following the acquisition of the parent company by Novo Holdings, the site continues to play a critical role in the global pharmaceutical supply chain.